Trial Profile
A prospective study of efficacy and safety of lenvatinib in patients with RAI-refractory differentiated thyroid cancer patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms Liberty
- 13 May 2016 New trial record